Literature DB >> 17141520

Endocannabinoids and the control of energy balance.

Isabel Matias1, Vincenzo Di Marzo.   

Abstract

Two receptors have been cloned to date for the psychotropic compound Delta(9)-tetrahydrocannabinol, and termed cannabinoid CB(1) and CB(2) receptors. Their endogenous ligands, the endocannabinoids, have also been identified. CB(1) receptors and endocannabinoids are present in brain structures controlling energy intake and in peripheral cells (hepatocytes, adipocytes, pancreatic islet cells) regulating energy homeostasis. CB(2) receptors are more abundant in lymphocytes and macrophages, and participate in immune and inflammatory reactions. Metabolic hormones and peptides regulate the levels of the endocannabinoids and, hence, the activity of cannabinoid receptors in several tissues in a seemingly coordinated way. The endocannabinoids, particularly after stress and brief food deprivation, act in turn as local modulators of the expression and action of neurotransmitters, hormones and adipokines involved in metabolic control. Endocannabinoid overactivity seems to accompany metabolic and eating disorders and to contribute to the development of abdominal obesity, dyslipidemia and hyperglycemia. Accordingly, clinical trials have shown that CB(1) receptor antagonists are efficacious at reducing not only food intake, but also abdominal adiposity and its metabolic sequelae.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141520     DOI: 10.1016/j.tem.2006.11.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  103 in total

1.  Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.

Authors:  Jose M de Miguel-Yanes; Alisa K Manning; Peter Shrader; Jarred B McAteer; Anuj Goel; Anders Hamsten; Caroline S Fox; Jose C Florez; Josée Dupuis; James B Meigs
Journal:  Obesity (Silver Spring)       Date:  2011-06-02       Impact factor: 5.002

2.  2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism.

Authors:  Kwang-Mook Jung; Jason R Clapper; Jin Fu; Giuseppe D'Agostino; Ana Guijarro; Dean Thongkham; Agnesa Avanesian; Giuseppe Astarita; Nicholas V DiPatrizio; Andrea Frontini; Saverio Cinti; Sabrina Diano; Daniele Piomelli
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

Review 3.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

4.  Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Authors:  Laura H Jacobson; S Renee Commerford; Sarah P Gerber; Yu Alice Chen; Beatriz Dardik; Frederique Chaperon; Chad Schwartzkopf; Van Nguyen-Tran; Thomas Hollenbeck; Peter McNamara; Xiaohui He; Hong Liu; H Martin Seidel; Anne-Liese Jaton; Jesper Gromada; Sandra Teixeira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

Review 5.  The thrifty lipids: endocannabinoids and the neural control of energy conservation.

Authors:  Nicholas V DiPatrizio; Daniele Piomelli
Journal:  Trends Neurosci       Date:  2012-05-22       Impact factor: 13.837

6.  Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.

Authors:  Isabel González-Mariscal; Susan M Krzysik-Walker; Wook Kim; Michael Rouse; Josephine M Egan
Journal:  Mol Cell Endocrinol       Date:  2015-12-25       Impact factor: 4.102

7.  Rimonabant in rats with a metabolic syndrome: good news after the depression.

Authors:  V Di Marzo; A Szallasi
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

8.  Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats.

Authors:  Nicholas V DiPatrizio; Kenny J Simansky
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

Review 9.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.